Carfilzomib en dexamethason met of zonder daratumumab voor recidiverend of refractair multipel myeloom

Despite recent advances in therapeutic options, there remains an unmet need for treating patients with relapsed or refractory multiple myeloma (R/R MM). The multinational phase 3 CANDOR study randomized patients with R/R MM to carfilzomib-dexamethasone-daratumumab (KdD) or carfilzomib-dexametasone (Kd). Updated results of the study showed that the median progression-free survival was 28.6 months with KdD versus 15.2 months with Kd (HR 0.59; p<0.0001). The authors conclude that KdD is an emerging standard-of-care for patients with R/R MM.